98%
921
2 minutes
20
Background: Sensitive detection and quantification of cerebral glucose is desired.
Purpose: To quantify cerebral glucose by detecting the H1-α-glucose peak at 5.23 ppm in H magnetic resonance spectroscopy at 7 T.
Study Type: Prospective.
Subjects: Twenty-eight non-fasted healthy subjects (aged 20-28 years).
Field Strength/sequence: Short echo time stimulated echo acquisition mode (short-TE STEAM) and semi-localized by adiabatic selective refocusing (semi-LASER) at 7 T.
Assessment: Single voxel spectra were obtained from the posterior cingulate cortex (27-mL) using a 32-channel head coil. The H1-α-glucose peak in the spectrum with retrospective removal of the residual water peak was fitted using LCModel with a glucose basis set of only the H1-α-glucose peak. Conventional spectral analysis was performed with a glucose basis set of a full spectral pattern of glucose, also. Fitting precision was evaluated with Cramér-Rao lower bounds (CRLBs). The repeatability of glucose quantification via the semi-LASER sequence was tested.
Statistical Tests: Paired or Welch's t-test were used for normally distributed values. A P value of <0.05 was considered significant. The repeatability of measures was analyzed using coefficient of variation (CV).
Results: Removal of the residual water peak improved the flatness and stability of baselines around the H1-α-glucose peak and reduced CRLBs for fitting the H1-α-glucose peak. The semi-LASER sequence was superior to the short-TE STEAM in the higher signal-to-noise ratio of the H1-α-glucose peak (mean ± SD 7.9 ± 2.5, P < 0.001). The conventional analysis overfitted the H1-α-glucose peak. The individual CVs of glucose quantification by detecting the H1-α-glucose peak were smaller than the corresponding CRLBs.
Data Conclusion: Cerebral glucose concentration is quantitated to be 1.07 mM by detecting the H1-α-glucose peak in the semi-LASER spectra. Despite requiring long scan times, detecting the H1-α-glucose peak allows true glucose quantification free from the influence of overlapping taurine and macromolecule signals.
Evidence Level: 2 TECHNICAL EFFICACY STAGE: 1.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmri.28834 | DOI Listing |
Endocrine
September 2025
Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Acta Neurochir (Wien)
September 2025
Department of Neurosurgery, Medical University of Gdańsk, Gdańsk, Poland.
Purpose: Moyamoya disease (MMD) is a chronic cerebrovascular disorder characterized by progressive arterial stenosis and fragile collateral formation, elevating stroke risk. Revascularization is the standard treatment, yet up to 27% of patients experience ischemic events within a year due to bypass insufficiency. While digital subtraction angiography (DSA) remains the gold standard for assessing bypass function, it is invasive and time-consuming.
View Article and Find Full Text PDFEvolution
September 2025
Behavioural Ecology Group, Department of Biology, University of Copenhagen, Denmark.
Bird songs differ widely among species and can show peculiar phenotypes, such as extreme or unusual sound frequencies for a species' body size. Although birds can modulate sound frequency, size-related limitations prevent vocalizing efficiently (i.e.
View Article and Find Full Text PDFAnalyst
September 2025
Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou 350108, P. R. China.
: The objective of this study is to develop a straightforward and expeditious clinical detection method for meropenem. This study aims to introduce an innovative nanoenzyme design, thereby broadening the application of platinum nanomaterials in biological detection. It seeks to facilitate the portable detection of meropenem using commercial software.
View Article and Find Full Text PDFPediatr Infect Dis J
September 2025
Hospital Universitario "Dr. José Eleuterio González," Monterrey, México.
We analyzed 59 pediatric pertussis cases during Mexico's 2024-2025 outbreak. Mortality was 13.6%, with low maternal Tdap coverage (27.
View Article and Find Full Text PDF